Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
Public ClinicalTrials.gov record NCT02343939. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the efficacy, safety, and tolerability of entospletinib when administered as monotherapy or in combination with chemotherapy in adults with acute myeloid leukemia (AML).
Study identification
- NCT ID
- NCT02343939
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 148 participants
Conditions and interventions
Conditions
Interventions
- Entospletinib Drug
- Daunorubicin Drug
- Cytarabine Drug
- Decitabine Drug
- Azacitidine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 1, 2015 (Actual)
- Primary completion
- Sep 4, 2018 (Actual)
- Completion
- Feb 21, 2019 (Actual)
- Last update posted
- Nov 15, 2019
2015 – 2019
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA | Los Angeles | California | — | — |
| University of Chicago | Chicago | Illinois | — | — |
| Loyola University Medical Center | Maywood | Illinois | — | — |
| Indiana University | Indianapolis | Indiana | — | — |
| University of Kansas Medical Center Research Institute, Inc | Fairway | Kansas | — | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | — | — |
| Henry Ford Health System | Detroit | Michigan | — | — |
| Karmanos Cancer Institute | Detroit | Michigan | — | — |
| Weill Cornell Medical College - New York - Presbyterian Hospital | New York | New York | — | — |
| Duke Cancer Center | Durham | North Carolina | — | — |
| University Hospitals Case Medical Center | Cleveland | Ohio | — | — |
| Ohio State University | Columbus | Ohio | — | — |
| Oregon Health & Science University | Portland | Oregon | 97239 | — |
| Saint Francis Cancer Center | Greenville | South Carolina | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02343939, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 15, 2019 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02343939 live on ClinicalTrials.gov.